Effectiveness of Probiotic Use in Alleviating Symptoms of Irritable Bowel Syndrome: A Systematic Review.

Autor:	Umeano L; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Iftikhar S; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Alhaddad SF; Pediatric, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Paulsingh CN; Pathology, St. George's University School of Medicine, St. George's, GRD.; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Riaz MF; Internal Medicine, Rawalpindi Medical University, Rawalpindi, PAK., Garg G; Orthopedics, King's Mill Hospital, Sutton-in-Ashfield, GBR., Mohammed L; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2024 Apr 15; Vol. 16 (4), pp. e58306. Date of Electronic Publication: 2024 Apr 15 (Print Publication: 2024).
DOI:	10.7759/cureus.58306
Abstrakt:	Irritable bowel syndrome (IBS) is a common functional gastrointestinal (GI) condition, and changes in the gut microbiota's composition contribute to the development of symptoms. Although the precise mechanisms of probiotic use in the human body are not fully understood, probiotic supplements are believed to reduce symptoms, such as abdominal pain, by regulating neurotransmitters and receptors associated with pain modulation in IBS patients compared to placebo by altering the gut flora. This systematic review aimed to assess the most current randomized controlled trials (RCTs) on how probiotic supplementation affects the symptoms in people with IBS. The effects of probiotic supplements on IBS symptoms were studied in RCTs published between January 2018 and June 2023. After a search through PubMed and Google Scholar using the keywords probiotics, gut microbiota, irritable bowel syndrome, and IBS; eight articles matched the inclusion criteria and were reviewed. Four trials used a multistrain probiotic, whereas the remaining four trials examined the effects of a monostrain supplement. All eight trials came to the same conclusion: Probiotic treatment may significantly reduce symptoms. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2024, Umeano et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu